 |
||||
 |
||||
    |
||||
 |
||||
 |
||||
|
||||
This site is sponsored by Daiichi Sankyo, Inc., distributor and marketer of EVOXAC® (cevimeline HCI). EVOXAC is a registered trademark of Daiichi Pharmaceutical Co., Ltd.
EVOXAC is FDA approved only for the treatment of symptoms of dry mouth in patients with Sjögren's syndrome. EVOXAC is not approved for the treatment of dry eyes or other dryness associated with Sjögren's syndrome. Please click here for important safety information and the full prescribing information about the risks and benefits of taking EVOXAC. The information on this site is for general educational and informational purposes only. This information is not intended as a substitute for advice, treatment or recommendations from health care professionals. It is important to follow the advice of your physician and other health care professionals regarding your individual medical and health care needs. Should you have a medical condition, you are advised to promptly see your physician or other health care professional. Daiichi Sankyo is not engaged in rendering medical advice. This site is intended for use by residents of the United States only. Copyright © 2006 Daiichi Sankyo, Inc. All rights reserved. |
||||
